• Current Issue:
    1articles Vol.3(2022) , Issue 5
    Sort by
    Open Access
    Original Article
    N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas
    Aim: Lower grade gliomas [LGGs; World Health Organization (WHO) grades 2 and 3], owing to the heterogeneity of their clinical behavior, present a therapeutic challenge to  [...] Read more.
    Feng Yuan ... Chiyuan Ma
    Published: September 30, 2022 Explor Target Antitumor Ther. 2022;3:553–569
    DOI: https://doi.org/10.37349/etat.2022.00100
    This article belongs to the special issue Theranostic Frontiers in Neuro-Oncology
    Times Cited: 0